However, because cancer metabolism is influenced by the tumour microenvironment and can be compartmentalized between different cell populations [41–43], it will be important in the future to extend studies of ECI2 function and perhexiline response to more patient-derived pre-clinical models (eg. Explants or PDX) as a stepping stone to clinical trials. The gene discussed is ECI2; the disease is neoplasm.